Acute Graft Versus Host Disease [GvHD] Treatment Market Trend Analysis And Forecasts to 2027
The global Acute Graft Versus Host Disease [GvHD] Treatment market gathered revenue around USD 263.9 Million in 2020 and market is set to grow USD 632.9 Million by the end of 2027 and is estimated to expand at a modest CAGR of 8.9% during the prediction period 2021 to 2027.
![Acute Graft Versus Host Disease [GvHD] Treatment Market Size 2020 to 2027](../reportimg/Acute-Graft-Versus-Host-Disease-[GvHD]-Treatment-Market-Size-2020-to-2027.jpg "Acute Graft Versus Host Disease [GvHD] Treatment Market Size 2020 to 2027")
The rise in focus on introducing novel effective therapeutics to address the unmet medical needs is anticipated to drive the global acute graft versus host disease (GvHD) treatment market from 2021 to 2027. North America is expected to account for significant share of the global acute graft versus host disease (GvHD) treatment market during the forecast period. The growth of the acute graft versus host disease (GvHD) treatment market in the region can be attributed to the presence of key players and rise in access to health care due to well-established healthcare infrastructure. The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2027. Emerging approached for mesenchymal stem cells (MSCs) to treat acute graft versus host disease (GvHD) in Japan is projected to boost the growth of market in the region.
The overview section of the report provides detailed qualitative analysis of drivers and restraints affecting the global acute graft versus host disease (GvHD) treatment market, along with opportunities in the global market
his research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Acute Graft Versus Host Disease [GvHD] Treatment market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Acute Graft Versus Host Disease [GvHD] Treatment market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Acute Graft Versus Host Disease [GvHD] Treatment market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
| Report Highlights | Details |
| Market Size | US$ 632.9 Million by 2027 |
| Growth Rate | CAGR of 8.9% From 2021 to 2027 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2027 |
| Segments Covered | Drug Class, Route of Administration,Distribution Channel,Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
| Companies Mentioned | Bristol-Myers Squibb, Novartis AG, Mesoblast Ltd, Equillium, Inc., Cynata Therapeutics Limited, MaaT Pharma, Incyte Corporation, Xenikos B.V., Merck & Co. (OncoImmune, Inc.), medac GmbH, and CSL Limited. |
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Some of the prominent players in the Acute Graft Versus Host Disease [GvHD] Treatment Market include: Bristol-Myers Squibb, Novartis AG, Mesoblast Ltd, Equillium, Inc., Cynata Therapeutics Limited, MaaT Pharma, Incyte Corporation, Xenikos B.V., Merck & Co. (OncoImmune, Inc.), medac GmbH, and CSL Limited.
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Highlights of the Report:
Research Methodology
In the study, a unique research methodology is utilized to conduct extensive research on the growth of the Acute Graft Versus Host Disease [GvHD] Treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the Acute Graft Versus Host Disease [GvHD] Treatment market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes the projections on the growth prospects of the Acute Graft Versus Host Disease [GvHD] Treatment markets more accurate and reliable.
Secondary Research
It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.
The secondary research sources referred in the process are as follows:
Primary Research
Primary research includes face-to face interviews, online surveys, and telephonic interviews.
Industry participants involved in this research study include:
Key Points Covered in Acute Graft Versus Host Disease [GvHD] Treatment market Study:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Acute Graft Versus Host Disease [GvHD] Treatment Market, By Drug Class
7.1. Acute Graft Versus Host Disease [GvHD] Treatment Market, by Drug Class, 2021-2027
7.1.1. Corticosteroids
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Immunosuppressive Agents
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Biological Therapy
7.1.3.1. Market Revenue and Forecast (2016-2027)
7.1.4. Kinase Inhibitors
7.1.4.1. Market Revenue and Forecast (2016-2027)
7.1.5. Monoclonal Antibody
7.1.5.1. Market Revenue and Forecast (2016-2027)
7.1.6. Mesenchymal Stem Cell (MSC)
7.1.6.1. Market Revenue and Forecast (2016-2027)
7.1.7. Others
7.1.7.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Acute Graft Versus Host Disease [GvHD] Treatment Market, By Route of Administration
8.1. Acute Graft Versus Host Disease [GvHD] Treatment Market, by Route of Administration, 2021-2027
8.1.1. Oral
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Topical
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Intravenous
8.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Acute Graft Versus Host Disease [GvHD] Treatment Market, By Distribution Channel
9.1. Acute Graft Versus Host Disease [GvHD] Treatment Market, by Distribution Channel, 2021-2027
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 10.Global Acute Graft Versus Host Disease [GvHD] Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.1.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.1.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.1.4.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.1.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.1.5.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.1.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.2.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.2.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.2.4.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.2.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.2.5.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.2.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.2.6.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.2.6.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.2.7.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.2.7.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.3.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.3.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.3.4.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.3.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.3.5.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.3.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.3.6.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.3.6.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.3.7.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.3.7.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.4.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.4.4.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.4.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.4.5.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.4.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.4.6.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.4.6.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.4.7.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.4.7.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.5.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.5.4.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.5.4.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)
10.5.5.2. Market Revenue and Forecast, by Route of Administration (2016-2027)
10.5.5.3. Market Revenue and Forecast, by Distribution Channel (2016-2027)
Chapter 11. Company Profiles
11.1. Bristol-Myers Squibb
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Novartis AG
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Mesoblast Ltd
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Equillium, Inc
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Cynata Therapeutics Limited
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. MaaT Pharma
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Incyte Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Xenikos B.V., Merck & Co
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. medac GmbH
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. CSL Limited.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers